Adaptimmune Therapeutics PLC expected to post a loss of 13 cents a share - Earnings Preview

Adaptimmune Therapeutics

12/11/2024 03:51

* Adaptimmune Therapeutics PLC  ADAP.OQ   ADAP.O  is
expected
to show a rise in quarterly revenue when it reports  results on
November 13 for the period ending September 30 2024
    * The Abingdon Oxfordshire-based  company is expected to
report a
52.7% increase in revenue to $11.173 million from $7.32 million
a year ago, according to the mean estimate from 8 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Adaptimmune Therapeutics
PLC
is for a loss of 13 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Adaptimmune
Therapeutics PLC is $2.50​, above​ its last closing price
of $0.82. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.05       -0.07      0.24      Beat    434.9
 Mar. 31 2024  -0.07       -0.10      -0.18     Missed  -83.7
 Dec. 31 2023  -0.08       -0.10      -0.24     Missed  -140​
 Sep. 30 2023  -0.12       -0.14      -0.20     Missed  -45.5
 ​​Jun.        -0.12       -0.13      -0.23     Missed  -72.8
 30 2023                                                
 Mar. 31 2023  -0.15       -0.15      0.01      Beat    104.1​
 Jan. 1 0001   -0.25       -0.25      -0.18     Beat    27.5
 Jan. 1 0001   -0.28       -0.24      -0.24     Met     0.7
 This summary was machine generated November 12 at 03:51 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)